AR and prostate cancer: While evidence for angiogenic activity of AR in breast cancer is sparse, regulation of angiogenesis by AR in prostate cancer is implicated through interactions with epigenetic and transcriptional co-activation factors to regulate VEGF, and synergy between anti-androgenic and anti-VEGF therapies [34].